1. Home
  2. Companies
  3. AGN
  4. Material Events

Argenica Therapeutics (ASX:AGN) — Material Events

ASX:AGN · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Argenica’s ARG-007 Shows Promising Functional Gains in Phase 2 Stroke TrialMedium
Argenica’s ARG-007 shows promising functional improvements in Phase 2 stroke trial, advancing Phase 2b plans
15 Oct 2025 ·Clinical Trial Results ·85
AI-Driven Analysis Uncovers ARG-007’s Breakthrough in Severe Stroke TreatmentHigh
AI Analysis Confirms ARG-007 Efficacy in Severe Stroke Patients, Paving Way for Targeted Phase 2b Trial
11 Dec 2025 ·Clinical Trial Results Announcement ·85
Argenica’s ARG-007 Phase 2 Stroke Trial Shows Safety and Efficacy Signal in High-Risk PatientsMedium
Argenica’s ARG-007 Phase 2 Stroke Trial Shows Safety and Efficacy Signal in High-Risk Patients
3 Sept 2025 ·Clinical Trial Results ·85
Argenica’s ARG-007 Clears Key FDA Hurdle with Tenecteplase CompatibilityMedium
Argenica’s ARG-007 passes key FDA drug interaction test with tenecteplase, advancing stroke therapy development
4 Dec 2025 ·ASX Announcement ·85
Argenica’s ARG-007 Shows Breakthrough Efficacy in Severe Stroke, Eyes Phase 2b TrialHigh
Argenica’s ARG-007 shows significant efficacy in severe stroke; plans Phase 2b trial and meets key FDA requirement
28 Jan 2026 ·Quarterly Activities & Cashflow Report ·85
Argenica Clears Key FDA Genotoxicity Test, Paving Way for Phase 2b TrialMedium
Argenica clears key FDA genotoxicity test, advancing IND application for ARG-007
21 May 2026 ·Regulatory Update ·85
Argenica Advances Phase 2b Stroke Trial With AI and Regulatory WinsMedium
Argenica advances Phase 2b stroke trial prep, secures EMA pediatric waiver, and reports $8M cash
29 Apr 2026 ·Quarterly Activities and Cashflow Report ·80
Argenica Completes Phase 2 Stroke Trial Dosing Amid FDA Clinical HoldHigh
Argenica completes Phase 2 dosing for stroke drug ARG-007; FDA places US IND on clinical hold
23 July 2025 ·Quarterly Activities & Cashflow Report ·Unexpected ·80
Argenica’s ARG-007 Clears Safety Hurdle, Eyes Targeted Phase 2b Stroke TrialMedium
Argenica’s ARG-007 Phase 2 stroke trial meets safety endpoint, shows efficacy signals in high-risk subgroup; plans Phase 2b trial
31 Oct 2025 ·Quarterly Activities & Cashflow Report ·80
Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial StartMedium
Argenica completes final FDA safety assay for ARG-007, advancing clinical trial plans
11 June 2026 ·Regulatory Update ·75
Argenica Secures EMA Paediatric Waiver, Fast-Tracking ARG-007 Stroke ApprovalMedium
Argenica secures EMA paediatric waiver for ARG-007 in stroke, accelerating European approval
2 Feb 2026 ·Regulatory Update ·75
Argenica Unveils FDA’s Path to Lift Clinical Hold on ARG-007 Stroke TrialMedium
Argenica receives FDA feedback detailing steps to lift clinical hold on ARG-007 stroke trial
14 Aug 2025 ·Regulatory Update ·75
Argenica Advances Stroke Drug Amid Rising Losses and FDA DialogueMedium
Argenica Therapeutics reports higher revenue and increased loss amid Phase 2 trial progress and FDA engagement
28 Aug 2025 ·Appendix 4E - Annual Report ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.